Aster (ASTER) Rebounds Above $1 on Nov. 6: $29M Buybacks, CZ’s 2M-Token Disclosure, and New Collateral Utility Fuel the Rally

Kraken Lists ASTER: Is This New DeFi Token the Next Big Thing?

6 November 2025

Dateline: November 6, 2025 — Aster’s native token ASTER extended its recovery today, reclaiming and holding the $1.00 mark after a turbulent week for crypto. Fresh buyback data, new on‑exchange utility, and lingering momentum from Changpeng “CZ” Zhao’s weekend disclosure that he purchased ~2 million ASTER are the key drivers behind the move. As of publication, ASTER hovered a little above the dollar level during its third straight session of gains. ^[1]

What changed today (Nov. 6)

Buybacks crossed 25.5M tokens (~$29.15M): On‑chain tallies show Aster’s official buyback wallet has accumulated 25.5 million ASTER since the program began, worth roughly $29.15 million at current prices. The team averaged ~2.76M tokens/day, and the current “S3” phase is slated to conclude on November 9, after which an airdrop utilizing the buyback wallet is planned. ^[2]
Market structure: third day up, testing resistance: Technical coverage today highlights a V‑shaped reversal with ASTER pushing into a trendline resistance area; the token’s improved collateral utility on its own DEX (details below) is cited as a near‑term bullish catalyst. ^[3]
Altcoin tone improved: After a broad sell‑off earlier in the week, market wrap pieces this morning noted ASTER among the day’s altcoin leaders as Bitcoin stabilized back above $100K. ^[4]

The week in brief: how we got here

Nov. 2 — CZ buys ASTER: CoinDesk reported that Binance founder CZ bought ~2 million ASTER, helping spark a near‑20% jump. Coverage also underscored the project’s 8B max supply and cautioned that narrative‑driven rallies can fade. ^[5]
Nov. 3–4 — Long squeeze hits; ASTER retests sub‑$1: Amid a market‑wide liquidation wave, ASTER’s intraday swings intensified. A CCN recap emphasized the token reclaiming $1 despite the broader deleveraging pressure. ^[6]
Nov. 5 — Utility upgrade: Aster enabled ASTER as trading collateral on its perpetuals venue with an 80% margin ratio, adding practical demand for the token only days after CZ’s disclosure. ^[7]
Nov. 6 — Whale defense of $1: Coverage today flagged a ~$6.47M spot purchase by a large holder that coincided with ASTER defending the $1 psychological level. ^[8]

Why the rebound may have legs (and what could spoil it)

1) Programmatic buybacks + airdrop carrot (near‑term)
The buyback program mechanically adds bid support while removing supply to a dedicated address ahead of the Nov. 9 milestone and subsequent airdrop. That combination can firm spot demand into the event window—though airdrop “sell the news” risk remains once tokens distribute. ^[9]

2) Real utility as collateral (structural)
Recognizing ASTER as DEX collateral (80% LTV) can deepen token utility beyond governance or incentives. If open interest expands with balanced funding, more traders may hold ASTER for margin, not just speculation—tightening circulating float during risk‑on stretches. ^[10]

3) Sentiment impulse from CZ’s disclosure (narrative)
High‑profile personal buys often spur short‑term momentum and wallet‑tracking flows. But as CoinDesk cautioned, narratives can overshoot fundamentals, especially with large token supplies and stiff competition among perp DEXs. ^[11]

Today’s price and market context

Live quote pages showed ASTER trading just above $1.00 at press time, up on the day but still inside a broader, volatile range. Market wraps also highlighted a modest altcoin recovery alongside Bitcoin’s bounce back above $100K after a mid‑week slide. ^[12]

Key levels to watch (near term)

Independent technical coverage this morning pointed to:

Resistance: a local trendline (near the $1.15 area) with extension risk toward ~$1.30 if broken decisively.
Support:$1.00 psychological and $0.93 (late‑October swing).
These levels frame the third straight session of upside; a failure back below the 4‑hour 50/100 EMA cluster would warn of a deeper pullback. ^[13]

What the optimists (and critics) are saying

Bull case: Sponsored commentary on Nov. 5 speculated that CZ’s involvement plus BNB‑ecosystem tailwinds could set up outsized upside for ASTER into Q4—a highly promotional view that sits well outside mainstream estimates. Treat “50x” talk as marketing, not analysis. ^[14]
Bear case: Even with buybacks, supply overhang (8B max) and competition from other high‑throughput perp venues cap valuation rerates unless volumes, fees, and protocol revenue scale sustainably. CoinDesk’s write‑up explicitly warned about narrative‑driven spikes. ^[15]

Calendar: near‑term catalysts

Through Nov. 9: S3 buyback phase concludes; airdrop expected using tokens held in the buyback address (timing and mechanics matter for flows). ^[16]
Ongoing: Monitoring of collateral utilization and funding/OI on the DEX after the utility change; watch if open interest rises on positive funding or flips as traders fade the move. ^[17]

The bottom line

For Nov. 6, ASTER’s story is about mechanics meeting momentum: consistent buybacks and a new collateral role have intersected with improving market tone, helping the token defend $1 and press into resistance. The next decisive cues are breakout acceptance above ~$1.15–$1.30 or a rejection that pushes the pair back to $1.00/$0.93 supports—with the Nov. 9 airdrop an obvious inflection point for flows. ^[18]

Sources & further reading (Nov. 6, 2025)

Buybacks & airdrop window: BlockBeats flash; also republished by Phemex News. ^[19]
Collateral utility & technical view: FXStreet analysis. ^[20]
Whale accumulation near $1: AMBCrypto. ^[21]
Altcoin market context (today): CryptoPotato daily market watch. ^[22]
Background on CZ’s purchase & token profile (8B max supply): CoinDesk (Nov. 2). ^[23]
Reclaiming $1 after liquidations: CCN recap picked up by Yahoo Finance. ^[24]
Live quote snapshot: Yahoo Finance ASTER page. ^[25]
Promotional/advertorial price‑prediction piece (context, not endorsement): Cryptonomist (Nov. 5). ^[26]

Disclosure: This article is for informational purposes and does not constitute investment advice. Crypto assets are highly volatile and involve significant risk.

ASTER Token Buyback Worth $140M Ignites Massive Rally! $4 Price Target? | BEST Wallet Raises $16.5M

Watch this video on YouTube.

References

1. phemex.com, 2. www.theblockbeats.info, 3. www.fxstreet.com, 4. cryptopotato.com, 5. www.coindesk.com, 6. www.ccn.com, 7. www.fxstreet.com, 8. ambcrypto.com, 9. www.theblockbeats.info, 10. www.fxstreet.com, 11. www.coindesk.com, 12. finance.yahoo.com, 13. www.fxstreet.com, 14. en.cryptonomist.ch, 15. www.coindesk.com, 16. www.theblockbeats.info, 17. www.fxstreet.com, 18. www.fxstreet.com, 19. www.theblockbeats.info, 20. www.fxstreet.com, 21. ambcrypto.com, 22. cryptopotato.com, 23. www.coindesk.com, 24. www.ccn.com, 25. finance.yahoo.com, 26. en.cryptonomist.ch

Tags:

Marcin Frąckiewicz Latest posts

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

View all

Is Elevance Health a Hidden Opportunity After a 24.5% Drop in 2025?
November 6, 2025, 7:28 AM EST. Elevance Health has tumbled in 2025 amid policy shifts and broader healthcare-sector volatility, with a year-to-date drawdown and a longer 24.5% slide that has investors rethinking value. The piece weighs near- and long-term catalysts, noting that a high valuation score isn't translating into certainty as government program changes loom for managed care. The core takeaway is a rigorous DCF assessment, which, using current free cash flow of $3.6B and projected growth, yields an intrinsic value around $1,090.84 per share-roughly 71% above current prices, signaling undervaluation. Still, equity investors should monitor the PE ratio, competitive dynamics, and policy risk, which could affect how quickly this perceived bargain translates into realized gains.
Inflammation Biotech Evommune Starts NYSE Trading in $150M IPO
November 6, 2025, 7:24 AM EST. Evommune is heading to the NYSE with a $150 million IPO to fund two clinical-stage assets. The Palo Alto biopharma is offering 9.3 million shares at $16 each, pricing in the $15-$17 range. Gross proceeds are $150 million, potentially rising by about $22.5 million if underwriters exercise their option for an additional 1.4 million shares. Trading under the ticker EVMN could begin today. The company plans to use the funds to advance two phase 2 programs, including EVO756, an oral MRGPRX2 antagonist being studied for CSU and atopic dermatitis (AD). Topline data for CSU from a phase 2 study showed 93% responses at four weeks. Data for AD topline in H2 2026. Evommune priced amid a broader biotech IPO backdrop as MapLight Therapeutics went public last week.
Arm Holdings Stock Surges on Q2 Beat, Strong AI Demand Lifts Outlook
November 6, 2025, 7:22 AM EST. Arm Holdings (ARM) stock jumps about 5-6% in pre-market trading after reporting a Q2 beat that topped revenue and earnings estimates and issuing stronger Q3 guidance. The company posted revenue of $1.14 billion, up 34% year over year, and EPS of $0.22, exceeds consensus of $0.13. Arm also raised its quarterly revenue guide to about $1.23 billion versus the $1.10 billion expected. Royalty revenue reached a record $620 million, up 21%, led by data centers, automotive, and IoT, with hyperscalers like Google, Amazon, and Microsoft boosting Arm-based deployments. Licensing revenue rose 56% to $515 million. The AI infrastructure buildout underscores demand for Arm's energy-efficient designs, and management hints at potential in-house chip development beyond licensing.
Capital One Stock Prediction: Analysts See Up to 29% Upside by 2027 on Discover Acquisition
November 6, 2025, 7:20 AM EST. Capital One (NYSE: COF) trades around $221 with an average target near $260, implying ~18% upside. Targets span $290 (high) and $210 (low), with a median near $258 and a mix of 14 Buys, 3 Outperforms, and 6 Holds. Growth projections call for revenue up about 19% annually through 2027, supported by operating margins near 48% and a forward multiple around 9.7x. A guided model points to ~$285/share by 2027, or about 29% total upside (12% annualized). The story centers on the Discover acquisition, expanded payments network, and stable credit trends amid solid consumer spending, though conviction remains modest and upside depends on continued earnings growth and credit stability.
Three Stocks Added to Zacks Rank #5 Strong Sell List on Nov. 6: ACHC, FWRD, CENX
November 6, 2025, 7:18 AM EST. Three names were added to Zacks Rank #5 (Strong Sell) today: Acadia Healthcare (ACHC), Forward Air (FWRD), and Century Aluminum (CENX). For the current year, earnings estimates were revised downward by 3.2%, 12%, and 11.7% over the last 60 days, respectively. The update reinforces the Strong Sell roster per Zacks research. The piece also highlights a separate feature on a stock most likely to double and a prompt to download Zacks' top stock ideas.